Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAL0140 in Chronic Kidney Disease
NCT07647133Phase 2Not yet recruiting
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Jun 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SAL0140 in chronic kidney disease (CKD) (3 arms), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. Primary endpoint: Baseline change of Urine Albumin-Creatinine Ratio at 16 weeks. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
SAL0140
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07647133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07647133.